Results 231 to 240 of about 116,117 (334)

Regulation of phage therapy medicinal products: developments, challenges, and opportunities. [PDF]

Front Cell Infect Microbiol
Fuerst-Wilmes M, Respondek V, Schramm M, Lilienthal N, Buss K, Duechting A.   +5 more
europepmc   +1 more source

Detection of Diagnostic Antibodies in Immune‐Mediated Diseases: A Focus on Antigens and Technologies

ChemBioChem, Volume 27, Issue 9, 14 May 2026.
This review explores autoantibody detection in immune‐mediated diseases, highlighting autoantigens including post‐translational modifications. We compared enzyme‐linked immunosorbent assay and indirect immunofluorescence with automated chemiluminescence platforms.
Silvia Bracci, Feliciana Real‐Fernandez, Federico Pratesi, Francesca Nuti, Paolo Rovero, Anna Maria Papini   +5 more
wiley   +1 more source

Phage therapy as a revitalized weapon for treating clinical diseases. [PDF]

Microbiome Res Rep
Wang Y, Yu Y.
europepmc   +1 more source

Phage therapy to treat unresponsive infections: A primer for the clinical microbiology laboratory staff

Josephine M. Davey-Young, Dinuri D. Punchihewa, Bernadette Ng, Jenna Wong, Greg J. German   +4 more
openalex   +1 more source

Contemporary Applications of Chemical Libraries for Drug Discovery and Methods for Their Synthesis

ChemistryEurope, Volume 4, Issue 5, May 2026.
Screening of chemical libraries has over the past decades become a cornerstone of drug discovery. Today, a broad range of chemical libraries exist but they are often not well described in terms of diversity. This review describes current efforts which aim to visualize chemical diversity in compound collections and discuss current trends in synthetic ...
Tobias N. Hansen, Nils J. V. Hansen
wiley   +1 more source

Liposome-encapsulated bacteriophages for enhanced oral phage therapy against Salmonella spp

Cano-Sarabia Mary
openalex   +1 more source

Repurpose an FDA‐Approved Antibody Using DARPin‐Scaffolded Bridge Protein

Chemistry–Methods, Volume 6, Issue 5, May 2026.
The cell line and scalable upstream/downstream process development needed for every new monoclonal antibody are both highly expensive and time‐consuming, significantly increasing the cost of new antibody therapeutics. By contrast, the production of many synthetic binders can be accomplished rapidly and with lower production costs.
Michael Woolley, Joshua D. Bryant, Samuel Vrana, Karuppiah Chockalingam, Zhilei Chen   +4 more
wiley   +1 more source

Phage Therapy in Plant Disease Management: 110 Years of History, Current Challenges, and Future Trends. [PDF]

Plants (Basel)
Pertics BZ, Király L, Bozsó Z, Krüzselyi D, Nagy JK, Künstler A, Samu F, Schwarczinger I.   +7 more
europepmc   +1 more source

Gut Dysbiosis as a Shared Mechanism in Obesity and Hypertension: Exploring a Promising Therapeutic Avenue

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 3, May 2026.
This review synthesises current knowledge on gut microbiome involvement in obesity and hypertension, evaluates microbiome‐based therapeutic strategies, and identifies critical research gaps to guide future investigations aimed at mitigating the dual pandemics.
Andrej Belančić, Almir Fajkić, Yusuf Ziya Sener, Ana Jelaković, Lejla Alić, Elvira Meni Maria Gkrinia, Donatella Verbanac, Bojan Jelaković   +7 more
wiley   +1 more source

Phage therapy for intestinal infections: efficacy, challenges, and future directions in translational research. [PDF]

Front Microbiol
Wang X, Li J, Ge Z, Fan J, Ma D, Cao H, Shen J, Wang Y, Liu Z, Gomaa SE, Li X, Ji X, Teng T.   +12 more
europepmc   +1 more source